The 12-16-week open-label study evaluated Ruxoprubart as monotherapy in treatment-naïve PNH patients. Key findings include: CLEVELAND, March 09, 2026 (GLOBE NEWSWIRE) -- NovelMed Therapeutics Inc., a ...

Creative Biolabs’ expanded primary neuron portfolio includes cortical, hippocampal, dopaminergic, and sensory neurons isolated and characterized under stringent quality control (QC) standards and ...

ABA Committee Urges Inclusion of Alternative Licensure Pathways Language in Accreditation Standards The Standards Committee reviewed Standard 316 in light of the recent developments that several U.S.

MetaCyc ( http:// metacyc. org) contains experimentally determined biochemical pathways to be used as a reference database for metabolism. In conjunction with the ...

Ali Morpeth, co-founder of the Planeatry Alliance, suggests that alternative proteins have reached a pivotal moment, and how the food system adapts them is the next big hurdle. For much of the past ...

Complement 3 glomerulopathy (C3G) is a rare kidney disease that is also considered an autoimmune disorder. There is no single cure for C3G, but several treatments may slow disease progression, protect ...

HOUSTON, TX, January 15, 2026 (EZ Newswire) -- Mars Materials ("MM" or the Company), a company working to store captured carbon dioxide into everyday products, today announced its selection into Shell ...

There are two types of complement 3 glomerulopathy: dense deposit disease (DDD) and C3 glomerulonephritis (C3GN). DDD often begins earlier in life and may progress more quickly. Both are linked to an ...

A health system–wide lipid screening pathway significantly increased pediatric screening rates across a large primary care network. A structured, system-wide clinical pathway increased pediatric lipid ...

Department of Rheumatology, Toronto University, Toronto, ON, Canada. Department of Rheumatology, Toronto University, Toronto, ON, Canada. Department of Internal Medicine, Qatif Central Hospital, Qatif ...

Abstract: The paper develops a Personalized Adaptive Learning Pathway System (PALPS) which adaptively designs streamlined educational programs for compiler design courses. The system deals with three ...

The last time I spoke about Omeros Corporation (OMER) it was in a Seeking Alpha article entitled "Omeros: FDA Appeal On Nasoplimab And Several 2023 Catalysts On Deck." Since then, it has faced several ...